On 29 September 2026 the FDA recorded a supplement to an abbreviated new drug application for a generic clozapine product. The public record names only the application and manufacturer; it does not describe what the supplement changes, and supplements of this kind commonly cover manufacturing, labelling or packaging updates.
Nothing in the notice signals a new safety concern or a change to clozapine's indications. Monitoring requirements for clozapine are set by each regulator, so the local rules — not a US generic supplement — continue to govern practice here.
- This is an administrative supplement to a generic application, not a safety communication.
- No change to clozapine's indication or warnings is described in the notice.
- Keep following your local regulator's neutrophil monitoring requirements for clozapine.
- When a patient's clozapine brand or manufacturer changes, recheck tolerability and, where available, levels.
Why it matters
Generic supply changes are a common, overlooked moment for clozapine levels and tolerability to shift.
Don't overread it
A licence supplement is not a new indication or a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for psychiatry, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free